Research graph
References from Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s1473-3099(23)00650-3
10.1016/s1473-3099(23)00650-3 · External reference
10.1038/s41467-025-55843-9
10.1038/s41467-025-55843-9 · External reference
10.1016/j.ymthe.2025.09.011
10.1016/j.ymthe.2025.09.011 · External reference
10.1038/s41598-019-43422-0
10.1038/s41598-019-43422-0 · External reference
10.1016/j.ymthe.2024.12.055
10.1016/j.ymthe.2024.12.055 · External reference
Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA
2025 · External reference
10.1038/s41590-022-01168-4
10.1038/s41590-022-01168-4 · External reference
10.1038/s41541-025-01124-x
10.1038/s41541-025-01124-x · External reference
10.1021/acsnano.4c08490
10.1021/acsnano.4c08490 · External reference
10.1016/j.immuni.2022.10.014
10.1016/j.immuni.2022.10.014 · External reference
10.1038/s41551-024-01256-w
10.1038/s41551-024-01256-w · External reference
10.1038/s41565-025-01974-5
10.1038/s41565-025-01974-5 · External reference
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
10.1016/j.cell.2025.11.023 · 2025 · External reference
10.1038/s41590-022-01160-y
10.1038/s41590-022-01160-y · External reference
10.1016/j.ymthe.2017.08.006
10.1016/j.ymthe.2017.08.006 · External reference
10.1038/s41467-025-68080-x
10.1038/s41467-025-68080-x · External reference
10.1038/s41590-022-01163-9
10.1038/s41590-022-01163-9 · External reference
10.1073/pnas.2309472120
10.1073/pnas.2309472120 · External reference
10.1016/j.jconrel.2021.12.008
10.1016/j.jconrel.2021.12.008 · External reference
10.1016/j.ymthe.2023.06.017
10.1016/j.ymthe.2023.06.017 · External reference
Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure
10.1016/j.jconrel.2017.09.018 · 2017 · External reference
10.1021/acsnano.0c00326
10.1021/acsnano.0c00326 · External reference
10.1038/s41565-025-01961-w
10.1038/s41565-025-01961-w · External reference
10.1016/j.omtn.2022.11.024
10.1016/j.omtn.2022.11.024 · External reference
10.1016/j.jconrel.2021.08.029
10.1016/j.jconrel.2021.08.029 · External reference
10.1016/j.omtn.2023.102083
10.1016/j.omtn.2023.102083 · External reference
10.3390/vaccines7030096
10.3390/vaccines7030096 · External reference
Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design
10.4049/jimmunol.1601877 · 2017 · External reference
10.1101/2025.03.09.642244
10.1101/2025.03.09.642244 · External reference
10.1016/j.molmed.2017.01.006
10.1016/j.molmed.2017.01.006 · External reference
The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration
10.1016/j.omtn.2020.09.004 · 2020 · External reference
10.1016/j.omtn.2025.102623
10.1016/j.omtn.2025.102623 · External reference
cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
10.1158/2326-6066.cir-24-0804 · 2025 · External reference
10.1021/acsnano.4c14102
10.1021/acsnano.4c14102 · External reference
An mRNA vaccine elicits STING-dependent antitumor immune responses
10.1016/j.apsb.2022.11.013 · 2023 · External reference
cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice
10.1016/j.omtn.2022.10.024 · 2022 · External reference
10.1038/s41565-024-01624-2
10.1038/s41565-024-01624-2 · External reference
10.1021/acs.nanolett.2c04883
10.1021/acs.nanolett.2c04883 · External reference
10.1016/j.ymthe.2021.03.002
10.1016/j.ymthe.2021.03.002 · External reference
10.1038/s41587-019-0247-3
10.1038/s41587-019-0247-3 · External reference
10.3389/fimmu.2020.616450
10.3389/fimmu.2020.616450 · External reference
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
10.1016/j.omtn.2019.07.014 · 2019 · External reference
Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy
10.1021/acscentsci.3c01310 · 2024 · External reference
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
10.1016/j.jconrel.2024.08.016 · 2024 · External reference
10.1038/s41541-025-01202-0
10.1038/s41541-025-01202-0 · External reference
10.1007/s12551-016-0218-6
10.1007/s12551-016-0218-6 · External reference
Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses
10.1073/pnas.2409978122 · 2025 · External reference
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
10.1016/j.omtn.2023.102045 · 2023 · External reference
Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine
10.1016/j.jconrel.2024.06.007 · 2024 · External reference
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
10.1016/j.omtn.2021.06.008 · 2021 · External reference
10.1038/s41541-024-00932-x
10.1038/s41541-024-00932-x · External reference
10.1016/j.ymthe.2025.07.036
10.1016/j.ymthe.2025.07.036 · External reference
Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice
10.1126/scitranslmed.adu2085 · 2025 · External reference
10.1038/s41586-018-0705-y
10.1038/s41586-018-0705-y · External reference
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
10.1016/j.nano.2017.10.013 · 2018 · External reference
Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity
10.1111/imm.13429 · 2022 · External reference
10.1002/eji.201445132
10.1002/eji.201445132 · External reference
10.1016/j.ejphar.2016.04.024
10.1016/j.ejphar.2016.04.024 · External reference
10.1016/j.xcrm.2025.102415
10.1016/j.xcrm.2025.102415 · External reference
10.1038/ncomms15480
10.1038/ncomms15480 · External reference
10.1007/s11033-019-04994-2/figures/6
10.1007/s11033-019-04994-2/figures/6 · External reference
10.1128/spectrum.01674-22
10.1128/spectrum.01674-22 · External reference
10.1038/s41467-022-33721-y
10.1038/s41467-022-33721-y · External reference
10.1002/jev2.12199
10.1002/jev2.12199 · External reference
10.1038/s41586-024-07134-4
10.1038/s41586-024-07134-4 · External reference
10.1126/sciimmunol.ado9933
10.1126/sciimmunol.ado9933 · External reference
10.1101/2021.08.01.454662
10.1101/2021.08.01.454662 · External reference
10.1182/blood-2016-10-744441
10.1182/blood-2016-10-744441 · External reference
10.1038/s41586-026-10353-6
10.1038/s41586-026-10353-6 · External reference
STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN–Dependent and –Independent Immune-Regulatory Pathways
10.4049/jimmunol.2001317 · 2021 · External reference
10.1038/s41587-026-03099-z
10.1038/s41587-026-03099-z · External reference
10.1101/2025.09.30.679428
10.1101/2025.09.30.679428 · External reference
10.1126/science.1093620
10.1126/science.1093620 · External reference
Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses
10.1126/sciadv.aed8930 · 2026 · External reference
10.3389/fimmu.2022.794776
10.3389/fimmu.2022.794776 · External reference
10.1038/gt.2008.177
10.1038/gt.2008.177 · External reference
Polyanion Chemistry Engineers Ternary RNA Nanoparticle Structure/Function from the Inside-Out
10.1021/acsnano.5c19683 · 2026 · External reference
10.1002/mabi.202200424
10.1002/mabi.202200424 · External reference
10.1242/dev.166884
10.1242/dev.166884 · External reference
10.1002/eji.201445132
10.1002/eji.201445132 · ExternalCitation · doi-reference
10.1002/jev2.12199
10.1002/jev2.12199 · ExternalCitation · doi-reference
10.1002/mabi.202200424
10.1002/mabi.202200424 · ExternalCitation · doi-reference
10.1007/s11033-019-04994-2/figures/6
10.1007/s11033-019-04994-2/figures/6 · ExternalCitation · doi-reference
10.1007/s12551-016-0218-6
10.1007/s12551-016-0218-6 · ExternalCitation · doi-reference
An mRNA vaccine elicits STING-dependent antitumor immune responses
10.1016/j.apsb.2022.11.013 · ExternalCitation · doi-reference
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
10.1016/j.cell.2025.11.023 · ExternalCitation · doi-reference
10.1016/j.ejphar.2016.04.024
10.1016/j.ejphar.2016.04.024 · ExternalCitation · doi-reference
10.1016/j.immuni.2022.10.014
10.1016/j.immuni.2022.10.014 · ExternalCitation · doi-reference
Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure
10.1016/j.jconrel.2017.09.018 · ExternalCitation · doi-reference
10.1016/j.jconrel.2021.08.029
10.1016/j.jconrel.2021.08.029 · ExternalCitation · doi-reference
10.1016/j.jconrel.2021.12.008
10.1016/j.jconrel.2021.12.008 · ExternalCitation · doi-reference
Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine
10.1016/j.jconrel.2024.06.007 · ExternalCitation · doi-reference
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
10.1016/j.jconrel.2024.08.016 · ExternalCitation · doi-reference
10.1016/j.molmed.2017.01.006
10.1016/j.molmed.2017.01.006 · ExternalCitation · doi-reference
Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
10.1016/j.nano.2017.10.013 · ExternalCitation · doi-reference
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
10.1016/j.omtn.2019.07.014 · ExternalCitation · doi-reference
The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration
10.1016/j.omtn.2020.09.004 · ExternalCitation · doi-reference
Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA
10.1016/j.omtn.2021.06.008 · ExternalCitation · doi-reference
cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice
10.1016/j.omtn.2022.10.024 · ExternalCitation · doi-reference
10.1016/j.omtn.2022.11.024
10.1016/j.omtn.2022.11.024 · ExternalCitation · doi-reference
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
10.1016/j.omtn.2023.102045 · ExternalCitation · doi-reference
10.1016/j.omtn.2023.102083
10.1016/j.omtn.2023.102083 · ExternalCitation · doi-reference
10.1016/j.omtn.2025.102623
10.1016/j.omtn.2025.102623 · ExternalCitation · doi-reference
10.1016/j.xcrm.2025.102415
10.1016/j.xcrm.2025.102415 · ExternalCitation · doi-reference
10.1016/j.ymthe.2017.08.006
10.1016/j.ymthe.2017.08.006 · ExternalCitation · doi-reference
10.1016/j.ymthe.2021.03.002
10.1016/j.ymthe.2021.03.002 · ExternalCitation · doi-reference
10.1016/j.ymthe.2023.06.017
10.1016/j.ymthe.2023.06.017 · ExternalCitation · doi-reference
10.1016/j.ymthe.2024.12.055
10.1016/j.ymthe.2024.12.055 · ExternalCitation · doi-reference
10.1016/j.ymthe.2025.07.036
10.1016/j.ymthe.2025.07.036 · ExternalCitation · doi-reference
10.1016/j.ymthe.2025.09.011
10.1016/j.ymthe.2025.09.011 · ExternalCitation · doi-reference
10.1016/s1473-3099(23)00650-3
10.1016/s1473-3099(23)00650-3 · ExternalCitation · doi-reference
10.1021/acs.nanolett.2c04883
10.1021/acs.nanolett.2c04883 · ExternalCitation · doi-reference
Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy
10.1021/acscentsci.3c01310 · ExternalCitation · doi-reference
10.1021/acsnano.0c00326
10.1021/acsnano.0c00326 · ExternalCitation · doi-reference
10.1021/acsnano.4c08490
10.1021/acsnano.4c08490 · ExternalCitation · doi-reference
10.1021/acsnano.4c14102
10.1021/acsnano.4c14102 · ExternalCitation · doi-reference
Polyanion Chemistry Engineers Ternary RNA Nanoparticle Structure/Function from the Inside-Out
10.1021/acsnano.5c19683 · ExternalCitation · doi-reference
10.1038/gt.2008.177
10.1038/gt.2008.177 · ExternalCitation · doi-reference
10.1038/ncomms15480
10.1038/ncomms15480 · ExternalCitation · doi-reference
10.1038/s41467-022-33721-y
10.1038/s41467-022-33721-y · ExternalCitation · doi-reference
10.1038/s41467-025-55843-9
10.1038/s41467-025-55843-9 · ExternalCitation · doi-reference
10.1038/s41467-025-68080-x
10.1038/s41467-025-68080-x · ExternalCitation · doi-reference
10.1038/s41541-024-00932-x
10.1038/s41541-024-00932-x · ExternalCitation · doi-reference
10.1038/s41541-025-01124-x
10.1038/s41541-025-01124-x · ExternalCitation · doi-reference
10.1038/s41541-025-01202-0
10.1038/s41541-025-01202-0 · ExternalCitation · doi-reference
10.1038/s41551-024-01256-w
10.1038/s41551-024-01256-w · ExternalCitation · doi-reference
10.1038/s41565-024-01624-2
10.1038/s41565-024-01624-2 · ExternalCitation · doi-reference
10.1038/s41565-025-01961-w
10.1038/s41565-025-01961-w · ExternalCitation · doi-reference
10.1038/s41565-025-01974-5
10.1038/s41565-025-01974-5 · ExternalCitation · doi-reference
10.1038/s41586-018-0705-y
10.1038/s41586-018-0705-y · ExternalCitation · doi-reference
10.1038/s41586-024-07134-4
10.1038/s41586-024-07134-4 · ExternalCitation · doi-reference
10.1038/s41586-026-10353-6
10.1038/s41586-026-10353-6 · ExternalCitation · doi-reference
10.1038/s41587-019-0247-3
10.1038/s41587-019-0247-3 · ExternalCitation · doi-reference
10.1038/s41587-026-03099-z
10.1038/s41587-026-03099-z · ExternalCitation · doi-reference
10.1038/s41590-022-01160-y
10.1038/s41590-022-01160-y · ExternalCitation · doi-reference
10.1038/s41590-022-01163-9
10.1038/s41590-022-01163-9 · ExternalCitation · doi-reference
10.1038/s41590-022-01168-4
10.1038/s41590-022-01168-4 · ExternalCitation · doi-reference
10.1038/s41598-019-43422-0
10.1038/s41598-019-43422-0 · ExternalCitation · doi-reference
10.1073/pnas.2309472120
10.1073/pnas.2309472120 · ExternalCitation · doi-reference
Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses
10.1073/pnas.2409978122 · ExternalCitation · doi-reference
10.1101/2021.08.01.454662
10.1101/2021.08.01.454662 · ExternalCitation · doi-reference
10.1101/2025.03.09.642244
10.1101/2025.03.09.642244 · ExternalCitation · doi-reference
10.1101/2025.09.30.679428
10.1101/2025.09.30.679428 · ExternalCitation · doi-reference
Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity
10.1111/imm.13429 · ExternalCitation · doi-reference
Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses
10.1126/sciadv.aed8930 · ExternalCitation · doi-reference
10.1126/science.1093620
10.1126/science.1093620 · ExternalCitation · doi-reference
10.1126/sciimmunol.ado9933
10.1126/sciimmunol.ado9933 · ExternalCitation · doi-reference
Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice
10.1126/scitranslmed.adu2085 · ExternalCitation · doi-reference
10.1128/spectrum.01674-22
10.1128/spectrum.01674-22 · ExternalCitation · doi-reference
cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
10.1158/2326-6066.cir-24-0804 · ExternalCitation · doi-reference
10.1182/blood-2016-10-744441
10.1182/blood-2016-10-744441 · ExternalCitation · doi-reference
10.1242/dev.166884
10.1242/dev.166884 · ExternalCitation · doi-reference
10.3389/fimmu.2020.616450
10.3389/fimmu.2020.616450 · ExternalCitation · doi-reference
10.3389/fimmu.2022.794776
10.3389/fimmu.2022.794776 · ExternalCitation · doi-reference
10.3390/vaccines7030096
10.3390/vaccines7030096 · ExternalCitation · doi-reference
Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design
10.4049/jimmunol.1601877 · ExternalCitation · doi-reference
STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN–Dependent and –Independent Immune-Regulatory Pathways
10.4049/jimmunol.2001317 · ExternalCitation · doi-reference
